CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy. A CAR-T therapy for myeloma that is ...
Tell us about the control strategy you've implemented with AstraZeneca and its external partners. Over the last year, we worked to improve our control strategy for drug delivery devices. Our goal was ...
Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results